The ELANE Knockout NCI-H1299 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population derived from the NCI-H1299 human non-small cell lung carcinoma cell line, in which the ELANE gene has been disrupted to create a loss-of-function model. By leveraging CRISPR/Cas9-mediated gene disruption, this polyclonal pool offers a genetically heterogeneous system that abrogates ELANE-dependent proteolytic activity, providing a versatile platform for functional studies without clonal selection artifacts. Researchers can utilize these cells to investigate the consequences of ELANE deficiency in a well-characterized lung adenocarcinoma background, enabling robust and reproducible experimental designs.
NCI-H1299 is a widely utilized human lung adenocarcinoma cell line isolated from a lymph node metastasis of a male patient. These cells display an epithelial morphology and harbor a homozygous partial deletion of the TP53 gene, resulting in p53 deficiency, which is a hallmark of many aggressive cancers. This genetic background makes NCI-H1299 particularly valuable for probing tumor suppressor pathways, oncogenic signaling, and metastatic mechanisms in non-small cell lung carcinoma. The cell line??s adaptability to various culture conditions and its extensive characterization in cancer research underscore its suitability as a host for knockout models, including those targeting microenvironment-modifying factors like ELANE.
ELANE encodes neutrophil elastase, a serine protease that plays a critical role in degrading extracellular matrix (ECM) components such as elastin and collagen, thereby facilitating tissue remodeling and neutrophil extravasation during innate immune responses. Its expression is transcriptionally regulated by key myeloid transcription factors, including CEBPA, CEBPE, and PU.1, and is further induced by G-CSF signaling and pro-inflammatory stimuli like TNF-alpha and IL-1beta. Once secreted, neutrophil elastase exerts its effects by cleaving ECM proteins, activating matrix metalloproteinases (e.g., MMP9), and modulating cytokine bioavailability??most notably through proteolytic processing of IL-8 and TNF-alpha. The enzyme??s activity is tightly controlled by endogenous inhibitors, principally alpha-1 antitrypsin (encoded by SERPINA1), as well as alpha-2 macroglobulin and secretory leukocyte protease inhibitor. In signaling terms, ELANE interfaces with the TLR4/MyD88 pathway, linking extracellular proteolysis to intracellular inflammatory cascades and amplifying immune effector functions.
In the NCI-H1299 lung cancer context, ELANE knockout disrupts elastase-mediated ECM remodeling and may profoundly alter the tumor microenvironment by dampening inflammatory cytokine networks and reducing proteolytic activation of growth factors. Since NCI-H1299 cells are p53-deficient and derived from a metastatic site, abrogation of ELANE creates a powerful model to dissect the crosstalk between serine protease activity and cancer hallmarks such as invasion, immune evasion, and angiogenesis. This system allows for the study of how neutrophil-derived proteases influence tumor behavior even in non-immune cell types that may express ELANE ectopically or respond to paracrine elastase signaling, thus providing insights into tumor?Cstroma interactions and potential therapeutic vulnerabilities.
The ELANE Knockout NCI-H1299 Polyclonal Cells are ideally suited for a broad array of functional applications in lung adenocarcinoma research. Typical assays include cell proliferation, apoptosis, and migration/invasion studies using Boyden chamber systems to evaluate the impact of ELANE loss on metastatic potential. These cells can be integrated into co-culture experimental setups with neutrophils to examine tumor?Cimmune cell interplay and protease-dependent paracrine effects. Furthermore, they serve as a valuable tool for pharmacological testing of elastase inhibitors and for mechanistic investigations of ELANE-related signaling through techniques such as RT-qPCR, Western blotting, and multiplex cytokine/chemokine profiling. This knockout model empowers researchers to explore pathways relevant to cyclic neutropenia, severe congenital neutropenia, and tumor-associated inflammation. For further information or to discuss customization options, please contact Ascent Research.
